| Prev Close | 324.71 |
| Open | 328.08 |
| Day Low/High | 324.71 / 333.28 |
| 52 Wk Low/High | 249.17 / 388.67 |
| Volume | 1.44M |
| Avg Volume | 1.24M |
Biogen Inc. (BIIB)
332.87
8.16
2.51
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 196.71M |
| Market Cap | 63.87B |
| EPS | 21.60 |
| P/E Ratio | 15.05 |
| Div & Yield | N.A. (N.A) |
Latest News
Biogen's Slump Is Likely to Continue
Avoid the long side of Biogen as the October low is likely to be tested or broken in the days ahead.
The Real Money Post-Industrial Average Has Jumped 11% So Far This Year
For the month of November RMPIA climbed 1.2% month over month.
Real Money Post-Industrial Average Beat Nasdaq Comp in November's First Half
Our index of 30 cutting-edge companies fell ... but not as much as the Nasdaq did.
Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter
Straying from these names could land you in quicksand as the 4th quarter begins.
Big Swings in Biogen Make It Hard to Take New Positions
Short-term price action may be volatile, but this name is still bullish long term.
The Race to Cure Alzheimer's is On: These Are the Forerunners
Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.
Jim Cramer: We've Got an Extremist Market
Don't buy up when there's nothing but rampant pin action.
2 Small Biotechs I Like in the Second Half
Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.
Biogen Stock: A Long-Term Bullish Perspective
After Friday's surge another look at BIIB is warranted.
Jim Cramer: The Strength in Pharma, Health Care and Real Estate Is Transient
The seemingly terrific rationales for strength in these economically sensitive sectors seem glib until the bigger global economic issues get resolved.
Video: Jim Cramer on the Jobs Report, Tariffs and Biogen
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending market topics from the floor of the New York Stock Exchange.
Biogen, Eisai Aim to Bring Their Alzheimer Drug to Market
Real Money reveals the crucial component Biogen got right in this trial and what it plans for the drug next.
Biotech Stocks Rally on Biogen's Landmark Test
Investors might be finally recognizing the hidden value of the firms' drug research and development.
Midday Musings
At midday tech, biotech ( dragging the group higher), homebuilders and energy are leading to the upside. There are really no large underperformers - though on a relative sense, autos, cap goods and semis are trailing. Banks fell initially, on the "d...
Biogen: Let the Situation Cool Off a Bit Before Buying
There are issues in the study that are keeping some buyers cautious and causing selling into the early strength.
Gilead Sciences Is Displaying a Bullish Long-Term Pattern
This biotech's weekly chart is very encouraging.
Exposure to Feverish Biogen Should Give These 2 Biotech ETFs Booster Shots
First Trust NYSE Arca Biotechnology Index Fund and iShares Nasdaq Biotechnology ETF look like two ways to catch the rally in Biogen.
Biogen Soars, and It May Signal a Breakout Gap to Further Gains
My longer-term price target is now $416.
Biogen Can Do More For the Bulls
Charts suggest that shares of Biogen have farther to run.
Emboldened By Biotech Names
For the trade, I'm opting to use the iShares Nasdaq Biotechnology ETF.
Biogen Is Set for a Tradable Rally
BIIB looks like it can rally at least 10% from here.
Video: Jim Cramer on Tesla, Biogen, Celgene and Groupon
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending stocks from the floor of the New York Stock Exchange.
Here's My Take on Biotech Stocks
I think M&A activity will pick up markedly going forward across the industry.
Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis
Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.
Biogen Is In a Downtrend With Further Risk Ahead
Charts are signalling more trouble ahead for the stock.
